A Scoring Index for Disease Activity in Canine Inflammatory Bowel Disease

Journal of Veterinary Internal Medicine

Volumn 17, Issue 3, 2003, Pages 291-297

  Jergens, Albert E ^a,c   Schreiner, C Alan ^a   Frank, Dagmar E ^a   Niyo, Yosiya ^a   Ahrens, Franklin E ^a   Eckersall, P D ^b   Benson, Tammy J ^a   Evans, Richard ^a  

^a Department of Statistics Center for Statistics and Applications in Forensic Evidence Iowa State University 2438 Osborn Dr Ames   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c IOWA STATE UNIVERSITY   (United States)

Author keywords

Acute phase protein; C reactive protein; Dog; Lymphocytic plasmacytic enteritis

Indexed keywords

ACUTE PHASE PROTEIN; AMYLOID A PROTEIN; C REACTIVE PROTEIN; HAPTOGLOBIN; OROSOMUCOID; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; METRONIDAZOLE; PREDNISONE; RANITIDINE; SALAZOSULFAPYRIDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOG DISEASE; ENTERITIS; EVALUATION; GASTROSCOPY; NONHUMAN; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SPECIES COMPARISON; STOMACH BIOPSY; TISSUE SECTION; AGING; ANIMAL; ANIMAL DISEASE; CLINICAL TRIAL; DIET; DOG; DRUG COMBINATION; FEMALE; MALE; PATHOLOGY;

ANIMALIA; CANIS FAMILIARIS;

AGING; ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; DIET; DOG DISEASES; DOGS; DRUG THERAPY, COMBINATION; FEMALE; HISTAMINE H2 ANTAGONISTS; INFLAMMATORY BOWEL DISEASES; MALE; METRONIDAZOLE; PREDNISONE; RANITIDINE; SULFASALAZINE;

EID: 0037805712     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2003)017<0291:ASIFDA>2.3.CO;2     Document Type: Article

References (51)

1. Sherding RG. Diseases of the small bowel. In: Ettinger SJ, ed. Textbook of Veterinary Internal Medicine, 2nd ed. Philadelphia, PA: WB Saunders; 1982:1278-1346.
2. Strombeck DR. Chronic inflammatory bowel disease. In: Strombeck DR, ed. Small Animal Gastroenterology. Davis, CA: Stonegate Publishing; 1979:240-261.
3. Jergens AE, Moore FM, Haynes JS, et al. Idiopathic inflammatory bowel disease in dogs and cats: 84 cases (1987-1990). J Am Vet Med Assoc 1992;201:1603-1608.
4. Guilford WG. Idiopathic inflammatory bowel diseases. In: Guilford WG, Center SA, Strombeck DR, et al, eds. Strombeck's Small Animal Gastroenterology. Philadelphia, PA: WB Saunders; 1996:451-486.
5. Jacobs G, Collins-Kelly L, Lappin M, et al. Lymphocytic-plasmacytic enteritis in 24 dogs. J Vet Intern Med 1990;4:45-53.
6. Jergens AE. Inflammatory bowel disease: Current perspectives. Vet Clin North Am Small Anim Pract 1999;29:501-521.
7. Jergens AE. Clinical staging for severity of inflammatory bowel disease. Proceedings of the 19th ACVIM Forum; 2001:722-723.
8. Best WR, Bectel JM, Singleton JW, et al. Development of the Crohn's disease activity index. Gastroenterology 1976;70:439-444.
9. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980;1:514.
10. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. BMJ 1955;2:1041-1044.
11. Van Hees PAM, Van Elteren PH, Van Lier HJJ, et al. An index of inflammatory activity in patients with Crohn's disease. Gut 1980; 21:279-286.
12. Prantera C, Davoli M, Lorenzetti F, et al. Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most. J Clin Gastroenterol 1988;10:41-50.
13. Dearing WH, McGuckin WH, Eleveback LR. Serum alpha-1-acid glycoprotein in chronic ulcerative colitis. Gastroenterology 1969; 56:295-303.
14. Fagan EA, Dyck RF, Maton PN, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 1982;12:351-360.
15. Jenson KB, Jarnum S, Koudhal G, et al. Serum orosomucoid ulcerative colitis. Its relation to clinical activity, protein loss and turnover of albumin and IgG. Scand J Gastroenterol 1976;11:177-193.
16. Andre C, Descos L, Landais P, et al. Laboratory supplementation of Crohn's disease activity index. Lancet 1980;2:594-595.
17. Andre C, Descos L, Landais P, et al. Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index. Gut 1981;22:571-574.
18. Saverymuttu SH, Hodgson HJF, Chadwick VS, et al. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut 1986;27:809-813.
19. Jergens AE, Schreiner CA, Ahrens FA, et al. Laboratory assessment of disease activity in canine inflammatory bowel disease. J Vet Intern Med 2000;14:347 (abstract).
20. Conner JG, Eckersall PD. Acute phase response in the dog following surgical trauma. Res Vet Sci 1988;45:107-110.
21. Hodgson HJF, Bhatti M. Assessment of disease activity in ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 1995;1:117-134.
22. Jergens AE, Gamet Y, Moore FM, et al. Colonic lymphocyte and plasma cell populations in canine lymphocytic-plasmacytic colitis: An immunohistochemical and morphometric study. Am J Vet Res 1999;60:515-520.
23. Jergens AE, Moore FM, Kaiser MS, et al. Morphometric evaluation of immunoglobulin A-containing and immunoglobulin G-containing cells and T cells in duodenal mucosa from healthy dogs and from dogs with inflammatory bowel disease or nonspecific gastroenteritis. Am J Vet Res 1996;57:697-704.
24. Gunawardana SC, Jergens AE, Ahrens FA, et al. Colonic nitrite and immunoglobulin G concentrations in dogs with inflammatory bowel disease. J Am Vet Med Assoc 1997;211:318-321.
25. Jergens AE, Carpenter SL, Wannemuehler Y, et al. Molecular detection of inducible nitric oxide synthase in canine inflammatory bowel disease. J Vet Intern Med 1998;12:205 (abstract).
26. Jergens AE, Sonea IM, Kauffman LK, et al. Cytokine mRNA expression in intestinal biopsies of dogs with spontaneous inflammatory bowel disease. Gastroenterology (abstract). In press.
27. Roth L, Walton AM, Leib MS, et al. A grading system for lymphocytic-plasmacytic colitis in dogs. J Vet Diagn Invest 1990;2: 257-262.
28. Stonehewer J, Simpson JW, Else RW, et al. Evaluation of B and T lymphocytes and plasma cells in colonic mucosa from healthy dogs and dogs with inflammatory bowel disease. Res Vet Sci 1998;65:59-63.
29. German AJ, Hall EJ, Day MJ. Immune cell populations within the duodenal mucosa of dogs with enteropathies. J Vet Intern Med 2001;15:14-25.
30. German AJ, Helps CR, Hall EJ, et al. Cytokine mRNA expression in mucosal biopsies from German shepherd dogs with small intestinal enteropathies. Dig Dis Sci 2000;45:7-17.
31. Wilcox B. Endoscopic biopsy interpretation in canine or feline enterocolitis. Semin Vet Med Surg 1992;7:162-171.
32. Jergens AE, Moore FM. Endoscopic biopsy specimen collection and histopathologic considerations. In: Tams TR, ed. Small Animal Endoscopy. Philadelphia, PA: Mosby; 1999:323-340.
33. Willard MD. Alimentary biopsies: Pitfalls, mistakes, and fallacies. Proceedings of the 19th ACVIM Forum; 2001:541-543.
34. Elwood CM, Garden OA. Gastrointestinal immunity in health and disease. Vet Clin North Am Small Anim Pract 1999;29:471-500.
35. Koj A, Gauldie J, Regoeczi E, et al. The acute-phase response of cultured rat hepatocytes. System characterization and the effects of human cytokines. Biochem J 1984;224:505-514.
36. Baumann H, Richards C, Gauldie J. Interaction among hepatocyte- stimulating factors, interleukin 1, and glucocorticoids for regulation of acute phase plasma proteins in human hepatoma (Hep G2) cells. J Immunol 1987;139:4122-4128.
37. Gauldie J, Richards C, Harnish D, et al. Interferon beta-2/B-cell stimulating factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 1987;84:7251-7255.
38. Volanakis JE. Acute phase proteins in rheumatoid diseases. In: McCarty Dkoopman W, ed. Arthritis and Allied Conditions: A Textbook of Rheumatology. Philadelphia, PA: Lea and Febiger; 1993:469-477.
39. Thompson D, Milford-Ward A, Whicher JT. The value of acute phase protein measurements in clinical practice. Ann Clin Biochem 1992;29:123-131.
40. Blackburn WD. Validity of acute phase proteins as markers of disease activity. J Rheumatol 1994;21(Suppl 42):9-13.
41. Biran H, Friedman N, Neumann L, et al. Serum amyloid A (SAA) variations in patients with cancer: Correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol 1986;39:794-797.
42. Riley RF, Zontine W. Further observations on the properties of dog C-reactive protein and the C-reactive protein response in the dog. J Lab Clin Med 1972;80:698-703.
43. Otabe K, Ito T, Sugimoto T, et al. C-reactive protein (CRP) measurement in canine serum following experimentally-induced acute gastric mucosal injury. Lab Anim 2000;34:434-438.
44. Chambers RE, Stross P, Barry RE, et al. Serum amyloid A protein compared with C-reactive protein, alpha-1 -antichymotrypsin, and alpha-1-acid glycoprotein as a monitor of inflammatory bowel disease. Eur J Clin Invest 1987;17:460-467.
45. Brignola C, Lanfranchi GA, Campieri M, et al. Importance of laboratory parameters in the evaluation of Crohn's disease activity. J Clin Gastroenterol 1986;8:245-248.
46. Kumon Y, Suehiro T, Hashimoto K, et al. Dexamethasone, but not IL-1 alone, upregulates acute-phase serum amyloid A gene expression and production by cultured human aortic smooth muscle cells. Scand J Immunol 2001;53:7-12.
47. Alsemegeest SP, Lambooy IE, Wierenga HK, et al. Influence of physical stress on the plasma concentration of serum amyloid-A (SAA) and haptoglobin (Hp) in calves. Vet Q 1995;17:9-12.
48. Harvey JW, West CL. Prednisone-induced increases in serum alpha-2-globulin and haptoglobin concentrations in dogs. Vet Pathol 1987;24:90-92.
49. McGrotty YL, Knottenbelt CM, Ramsey IK, et al. Haptoglobin as a marker of disease in a hospital population. J Vet Intern Med 2002; 16:387 (abstract).
50. Jarret IG. A polymeric form of haemoglobin-binding protein in sheep following metabolic and hormonal disturbance. Aust J Biol Sci 1972;25:941.
51. Hadziselimovic F, Emmons LR, Gallati H. Soluble tumour necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of treatment of inflammatory bowel disease. Gut 1995;37:260-263.